<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>350</serviceExecutionTime><Drug id="8678"><DrugName>labradimil</DrugName><DrugNamesKey><Name id="42759560">Cereport</Name><Name id="42815229">labradimil</Name></DrugNamesKey><DrugSynonyms><Name><Value>Cereport</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>lobradimil</Value></Name><Name><Value>RMP-7</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>receptor mediated permeabilizer-7, Alkermes</Value></Name><Name><Value>labradimil</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>159768-75-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14005">Alkermes plc</CompanyOriginator><CompaniesSecondary><Company id="14005">Alkermes plc</Company><Company id="14095">ALZA Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8678" type="Drug"><TargetEntity id="216365" type="siDrug">Labradimil</TargetEntity></SourceEntity><SourceEntity id="14005" type="Company"><TargetEntity id="4295905472" type="organizationId">Alkermes Inc</TargetEntity></SourceEntity><SourceEntity id="14095" type="Company"><TargetEntity id="4295903338" type="organizationId">ALZA Corp</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="206" type="ciIndication"><TargetEntity id="10027199" type="MEDDRA"></TargetEntity><TargetEntity id="D008581" type="MeSH"></TargetEntity><TargetEntity id="-1765797396" type="omicsDisease"></TargetEntity><TargetEntity id="892" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="239" type="ciIndication"><TargetEntity id="10015916" type="MEDDRA"></TargetEntity><TargetEntity id="D005128" type="MeSH"></TargetEntity><TargetEntity id="-2056365523" type="omicsDisease"></TargetEntity><TargetEntity id="754" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="760" type="ciIndication"><TargetEntity id="C71" type="ICD10"></TargetEntity><TargetEntity id="10061019" type="MEDDRA"></TargetEntity><TargetEntity id="D001932" type="MeSH"></TargetEntity><TargetEntity id="-927909969" type="omicsDisease"></TargetEntity><TargetEntity id="581" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="561" type="Action"><TargetEntity id="2753" type="Mechanism">Mitochondrial Permeability Transition (MPT) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="90" type="Action"><TargetEntity id="98" type="Mechanism">Bradykinin Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1108">Glioma</Indication><Indication id="206">Meningitis</Indication><Indication id="239">Ocular disease</Indication><Indication id="55">Cardiac failure</Indication><Indication id="760">Brain tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="90">Bradykinin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="561">Anticancer permeability enhancer</Action><Action id="388">Vasodilator</Action></ActionsSecondary><Technologies><Technology id="1263">Immuno-oncology</Technology><Technology id="604">CNS penetration enhancer</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-01-06T18:39:40.000Z</LastModificationDate><ChangeDateLast>2018-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Labradimil (receptor-mediated permeabilizer-7; RMP-7; Cereport), a blood-brain barrier permeability-enhancing bradykinin analog, was under development by &lt;ulink linkID="14005" linkType="Company"&gt;Alkermes&lt;/ulink&gt; and &lt;ulink linkID="14095" linkType="Company"&gt;ALZA&lt;/ulink&gt; for the improved delivery of other therapeutic agents, in particular &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; (qv) for the potential treatment of brain tumors [&lt;ulink linkID="271748" linkType="reference"&gt;271748&lt;/ulink&gt;], [&lt;ulink linkID="265225" linkType="reference"&gt;265225&lt;/ulink&gt;]. Development of labradimil in combination with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; in primary glioma, for which phase III trials had been initiated, was discontinued in April 1999. At this time, other trials were ongoing, including phase II trials in pediatric patients with brain tumors (conducted by the NCI) and adult patients with brain metastases from lung cancer [&lt;ulink linkID="320564" linkType="reference"&gt;320564&lt;/ulink&gt;]. However, the agreement with ALZA was terminated in December 2002, following which Alkermes discontinued development due to funding difficulties and the clinical trial results obtained to date [&lt;ulink linkID="499339" linkType="reference"&gt;499339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound had also been investigated as a blood-brain barrier permeability enhancer for the treatment of ocular disease and meningitis [&lt;ulink linkID="175743" linkType="reference"&gt;175743&lt;/ulink&gt;], [&lt;ulink linkID="271748" linkType="reference"&gt;271748&lt;/ulink&gt;], as well as as a coronary vasodilator [&lt;ulink linkID="348482" linkType="reference"&gt;348482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PRIMARY GLIOMA&lt;/subtitle&gt;A 250-patient phase III trial in primary glioma began in the first quarter of 1998. The trial compared labradimil plus &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; alone, with survival as the primary endpoint [&lt;ulink linkID="277893" linkType="reference"&gt;277893&lt;/ulink&gt;]. In April 1999, Alkermes discontinued the phase III trial and, at this time, did not plan to initiate any further clinical trials for this indication in the near future [&lt;ulink linkID="376222" linkType="reference"&gt;376222&lt;/ulink&gt;]. The decision to discontinue was not based on safety or efficacy issues, but on the determination that some elements of the study design were inappropriate and that the probability of a successful completion was low [&lt;ulink linkID="320564" linkType="reference"&gt;320564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A study measuring the permeability effects of labradimil in patients with primary malignant glioma using fast-computed tomography imaging technology (Fast CT) was reported at the Cerebral Vascular Biology Conference in 1995. Labradimil increased the permeability of brain tumors in patients and was associated with increases in permeability in the tumor periphery [&lt;ulink linkID="180668" linkType="reference"&gt;180668&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;RECURRENT MALIGNANT BRAIN TUMORS&lt;/subtitle&gt;In 1997, Alkermes commenced its third phase II study of labradimil administered iv in conjunction with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; to patients with recurrent, malignant brain tumors [&lt;ulink linkID="257741" linkType="reference"&gt;257741&lt;/ulink&gt;], [&lt;ulink linkID="266149" linkType="reference"&gt;266149&lt;/ulink&gt;]. Preliminary results of this 121-patient dose-ranging study (ALK01-017), reported in March 1997, showed that the study did not meet its primary endpoint of time taken for 50% tumor growth [&lt;ulink linkID="240366" linkType="reference"&gt;240366&lt;/ulink&gt;]. In December 1996, positive results had been reported from two European trials (ALK01- 013 and ALK01-019) for the same indication and administration route [&lt;ulink linkID="228779" linkType="reference"&gt;228779&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1996, Alkermes completed an open-label, multicenter phase II trial of labradimil in combination with the &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt;, administered intra-arterially in patients with recurrent, malignant brain tumors who had failed previous therapies [&lt;ulink linkID="296831" linkType="reference"&gt;296831&lt;/ulink&gt;], [&lt;ulink linkID="220336" linkType="reference"&gt;220336&lt;/ulink&gt;], [&lt;ulink linkID="203615" linkType="reference"&gt;203615&lt;/ulink&gt;]. Preliminary results from this trial, reported in September 1997, showed that the treatment was generally well tolerated, and resulted in positive responses in 63% of patients and overall median survival of 47 weeks [&lt;ulink linkID="261854" linkType="reference"&gt;261854&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PEDIATRIC BRAIN TUMORS&lt;/subtitle&gt;In August 1996, enrollment was initiated for an NCI phase I/II trial with labradimil and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt;, iv, in children with brain tumors to determine the safety and MTD in up to 24 children who had not responded to other therapies [&lt;ulink linkID="219445" linkType="reference"&gt;219445&lt;/ulink&gt;]. In April 1999, a phase II clinical trial in pediatric patients with brain tumors (conducted by the NCI) was ongoing [&lt;ulink linkID="320564" linkType="reference"&gt;320564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, clinical data from an NCI phase I study, investigating the pharmacokinetics of &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; administered with labradimil in 21 pediatric patients with brain tumors, were presented at the 94th AACR meeting, Washington, DC. &lt;ulink linkID="44383" linkType="Drug"&gt;Carboplatin&lt;/ulink&gt; and labradimil were administered on 2 consecutive days every 28 days, and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; was adaptively dosed on the basis of the radioisotope glomerular filtration rate (GFR) to achieve a target plasma AUC of 3.5 mg x min/ml per dose x 2 (2.5 mg x min/ml per dose x 2 in patients with prior craniospinal radiation or myeloablative chemotherapy). &lt;ulink linkID="44383" linkType="Drug"&gt;Carboplatin&lt;/ulink&gt; was infused over 60 min (n = 15) or 15 min (n = 6). The 10 min labradimil infusion began 5 min before the end of the &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; infusion. The median GFR was 63 (range: 38 to 95) ml/min/m2, and the median doses for the 2.5 and 3.5 mg x min/ml target AUCs were 157 (range: 124 to 235) mg/m2 and 276 (range: 179 to 360) mg/m2, respectively. The measured AUC exceeded the target AUC in all patients. The median &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; AUCs at the 2.5 and 3.5 mg x min/ml target AUCs were 3.36 (range: 2.51 to 5.78) mg/m2 and 4.82 (range: 3.90 to 7.70) mg/m2, respectively. There was no relationship between the ratio AUC measured:AUC target and labradimil dose. &lt;ulink linkID="44383" linkType="Drug"&gt;Carboplatin&lt;/ulink&gt; clearance (median 52 ml/min/m2, range: 31 to 70 ml/min/m2) correlated poorly with GFR (r2 = 0.16). Adaptive dosing of &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; based on GFR overestimated the dose required to achieve the targeted &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; AUC in pediatric patients receiving concurrent labradimil [&lt;ulink linkID="496912" linkType="reference"&gt;496912&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;BRAIN METASTASES FROM LUNG CANCER&lt;/subtitle&gt;In April 1996, Alkermes initiated a European phase I/II trial with labradimil and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; administered iv in 14 patients with brain tumor resulting from metastases from lung cancer [&lt;ulink linkID="205706" linkType="reference"&gt;205706&lt;/ulink&gt;], [&lt;ulink linkID="272744" linkType="reference"&gt;272744&lt;/ulink&gt;]. In April 1999, Alkermes was continuing with a phase II trial in adult patients with brain metastases from lung cancer [&lt;ulink linkID="320564" linkType="reference"&gt;320564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;INFECTIOUS DISEASES&lt;/subtitle&gt;By 1994, Alkermes had conducted a phase I/II study of labradimil in combination with amphotericin B in patients with cryptococcal meningitis [&lt;ulink linkID="175743" linkType="reference"&gt;175743&lt;/ulink&gt;]. By 1997, the drug had also been tested in pilot studies for the delivery of ganciclovir for the treatment of cerebrospinal viral infections [&lt;ulink linkID="271748" linkType="reference"&gt;271748&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Preclinical data presented at the Society for Neuroscience annual meeting in November 2000 demonstrated that the drug may be used in combination with low doses of cyclosporine-A (CsA) in order to effect protection against neurotoxicity induced by 6-hydroxydopamine. This was stated to provide a novel method for administering CsA, avoiding the toxicity associated with high doses [&lt;ulink linkID="390332" linkType="reference"&gt;390332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preclinical results presented in 1999 showed that labradimil was a potent systemic and coronary vasodilator, whose actions are mediated by nitric oxide and enhanced by autonomic reflex responses. The in vivo study was in six conscious dogs receiving infusions of labradimil (0.0025 to 0.02 microg/kg/min) before and after the development of heart failure induced by rapid pacing for 4 weeks [&lt;ulink linkID="348482" linkType="reference"&gt;348482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preclinical studies on rodents, reported in 1998, suggest that labradimil might also be useful for the intravascular delivery of viral gene therapy vectors in the treatment of brain tumors [&lt;ulink linkID="312396" linkType="reference"&gt;312396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Labradimil is a bradykinin B2 receptor agonist  [&lt;ulink linkID="271748" linkType="reference"&gt;271748&lt;/ulink&gt;], [&lt;ulink linkID="265225" linkType="reference"&gt;265225&lt;/ulink&gt;], [&lt;ulink linkID="348482" linkType="reference"&gt;348482&lt;/ulink&gt;]. By 1994, it had been shown that labradimil temporarily increases the permeability of the blood-brain barrier in animals which had radiation injuries in the brain or brain tumors [&lt;ulink linkID="167565" linkType="reference"&gt;167565&lt;/ulink&gt;], [&lt;ulink linkID="167452" linkType="reference"&gt;167452&lt;/ulink&gt;]. Following injection, labradimil binds to receptors on the blood-brain and blood-ocular barriers and triggers a brief relaxation of their tight cellular junctions. It does not itself bind to or serve as a carrier for co-administered compounds. It was postulated that drugs that could be administered along with labradimil included cancer chemotherapeutics and anti-infectives not currently used effectively in central nervous system and ocular disorders because of limited penetration into the blood-brain or blood-ocular barriers [&lt;ulink linkID="174603" linkType="reference"&gt;174603&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In 1992, Alkermes Clinical Partners LP was formed to fund the further development of labradimil. Alkermes transferred all its rights to Clinical Partners, entered into a product development agreement with the company and acquired rights to  purchase the partnership interests in the company. In total, Clinical Partners raised and spent $46 million from a private placement by June 1996 [&lt;ulink linkID="499339" linkType="reference"&gt;499339&lt;/ulink&gt;]. In October 1997, ALZA made a $10 million upfront payment to Alkermes to fund clinical development of labradimil; in return, ALZA gained an option to acquire exclusive worldwide commercialization rights [&lt;ulink linkID="265225" linkType="reference"&gt;265225&lt;/ulink&gt;]. The agreement with ALZA was terminated in December 2002. As a result of the difficulties encountered in the development of labradimil, including clinical trial results and the termination of the agreement with ALZA, Alkermes determined that development of Cereport was not economically feasible and decided not to commit additional funds to its development. By June 2003, Alkermes had abandoned patent rights relating to the compound and all receptor mediated permeabilizers outside the US and Canada. Rights to labradimil and the RMP technology reverted to Clinical Partners in the US and Canada [&lt;ulink linkID="499339" linkType="reference"&gt;499339&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Donald Kyle, Ph D, &lt;ulink linkType="Company" linkID="19831"&gt;Scios Nova Inc&lt;/ulink&gt;, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;RMP-7 is a nonapeptide agonist of B2 kinin receptors.  The molecule contains two unnatural amino acids, thienylalanine and 4-methylproline, at positions 5 and 7, respectively in the sequence.  In addition, the molecule contains a reduced amide bond linking tyrosine at position 8 with arginine at position 9.  The amide bond of this dipeptide is reduced first, the remainder of the sequence is then assembled via standard solid phase synthetic procedures.  Replacing L-Arg9 with D-Arg9 results in a compound which no longer has kinin agonist properties [&lt;ulink linkType="reference" linkID="169375"&gt;169375&lt;/ulink&gt;].  RMP-7 does not act via B1 kinin receptors.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;RMP-7 has been shown to act as a kinin agonist in vitro and in vivo.  In rat brain microvascular endothelial cultures, intracellular calcium release was effected via RMP-7 administration.  The magnitude and time course of the calcium signal was reportedly similar to that evoked by bradykinin [&lt;ulink linkType="reference" linkID="169375"&gt;169375&lt;/ulink&gt;].  The first step in the degradative pathway of the native kinins bradykinin and kalladin, is enzymatic cleavage of the Phe8-Arg9 amide bond.  Since the corresponding bond is reduced to a non-cleavable form in RMP-7, the presumption is that the duration of action is enhanced beyond that of the native ligands.&lt;/para&gt;&lt;para&gt;In rodents, RMP-7 has been shown to increase the permeability of tumor cells as measured by electron microscopy and radio-tracer molecules.  Mouse brains, from mice pretreated with RMP-7 (5 microg/kg) and the tracer La+3, showed La+3 penetration into the tight junctions, basal lamina and peripheral spaces of the midbrain and cerebral cortex.  Control animals showed less dramatic La+3 penetration [&lt;ulink linkType="reference" linkID="193296"&gt;193296&lt;/ulink&gt;].  In rat brain tumor models, RMP-7 enhances the delivery of radiolabeled tracers greatly to the tumor tissue with a much smaller effect on a delivery to the surrounding normal brain tissues.  Specifically rats with striatal RG2 tumors were given labeled &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; with a 15 minute infusion on RMP-7 (1 microg/kg/min.). Autoradiography showed a 2-fold increase in the amount of &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; in the tumor, compared to the controls.  No differences between RMP-7- and vehicle-treated groups were found in any other portions of the brain.  Survival time was also prolonged [&lt;ulink linkType="reference" linkID="193296"&gt;193296&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Uptake of tracers of various sizes has also been demonstrated, again using RG2 tumors (rat) and an infusion of 0.1 microg/kg/min RMP-7, through the intra-carotid artery.  The permeability of tumor capillaries to methotrexate, alpha-aminoisobutyric acid, sucrose, insulin and dextran was measured, and reported as a unidirectional rate constant Ki (microl/g/min).  The respective values for these tracers, administered with RMP-7 versus controls are: 35 versus 9 (methotrexate); 16 versus 9 (alpha-aminoisobutyric acid); 26 versus 9 (sucrose); 14 versus 7 (insulin) and 15 versus 2 (dextran).  The permeability of these RG2 gliomas, even to the large protein dextran (70000 D) was enhanced by 10-fold over controls [&lt;ulink linkType="reference" linkID="193299"&gt;193299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No formal toxicity studies have been reported, however adverse effects have been noted in certain clinical trials.  These include flushing, warmth, nausea, vomiting and headache.  It is important to note that these effects are mechanically consistent with kinin receptor activation, and might not be caused by chemical toxicity of RMP-7.  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I &lt;/subtitle&gt;In one trial, 38 healthy volunteers were treated with RMP-7 at a dose of 10 pg/kg and multiple doses (30-300 ng/kg iv) over 2-10 minutes for 7 days.  At the higher doses, a pattern of vasodilation-related events was noted.  These included flushing, warmth, nausea, and vomiting. Each resolved shortly after infusion.  When RMP-7 was infused for 10 minutes, the incidence and severity of these events was diminished.  Moreover, mild increases in heart rate and mean systolic blood pressure were noted, but resolved in 10 minutes. No hypotension was noted and no effects on ECG or EEG were seen [&lt;ulink linkType="reference" linkID="207251"&gt;207251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a similar trial, six HIV antibody positive adults were given increasing doses of RMP-7 on successive days (30 ng/kg, and 300 ng/kg).  The drug was infused over 2-10 minutes.  Results and side effect profile was comparable to the 38 patient trial [&lt;ulink linkType="reference" linkID="188825"&gt;188825&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II &lt;/subtitle&gt;Three phase II trials are ongoing for the use of RMP-7 with &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; for the treatment of recurrent glioma. No results have been reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;RMP-7 is a potent agonist of kinin B2 receptors.  Like the native ligand, bradykinin, RMP-7 has a diverse pharmacological profile. Nearly all cells express kinin receptors, and their activation leads to relaxation of venular smooth muscle and hypotension, smooth muscle contraction of the gut and airway, alteration of ion secretion from epithelial cells, production of nitric oxide, release of cytokines, etc. In short, bradykinin is known to be an important mediator of inflammation and pain.  &lt;/para&gt;&lt;para&gt;Capitalizing on the ability of bradykinin to increase vascular permeability as a novel mechanism to enhance the delivery of other drugs into tumors and across the blood-brain barrier is intriguing.  Indeed, the phase I data presented thus far for RMP-7 suggest that the idea works, and that the compound can be tolerated in low doses with varying degrees of patient discomfort.&lt;/para&gt;&lt;para&gt;This peptidic agent has a short half life, but that could be an advantage since increasing the permeability of the protective blood-brain barrier for extended periods of time might lead to further complications.  Most investigators have focused on the development of kinin receptor antagonists to be therapeutically used for asthma, arthritis, pain, rash, migraine, SIRS, and so on.  Hence, little effort has been spent developing kinin agonists for clinical use and RMP-7, therefore, has no real competitor at this time.&lt;/para&gt;&lt;para&gt;Adverse physiological effects associated with RMP-7 administration might be a major deterrent to its routine use.  However, this must be considered in the context of the adverse effects of certain chemotherapeutics which are already endured by patients.  If RMP-7 coadministration could offer the promise of shorter chemotherapy, and if increasing the permeability of the blood-brain barrier can be tolerated in these patients, then RMP-7 looks promising as a novel cooperative drug delivery molecule.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1108">Glioma</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="55">Cardiac failure</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14005">Alkermes plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="239">Ocular disease</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14005">Alkermes plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1108">Glioma</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="760">Brain tumor</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="206">Meningitis</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14095">ALZA Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1108">Glioma</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="499339" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>1999-11-29T00:00:00.000Z</StatusDate><Source id="348482" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="760">Brain tumor</Indication><StatusDate>1997-09-08T00:00:00.000Z</StatusDate><Source id="220336" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="760">Brain tumor</Indication><Source id="296416" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="239">Ocular disease</Indication><Source id="174603" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="206">Meningitis</Indication><Source id="175743" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><Source id="175183" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><Source id="187848" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14095">ALZA Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate>1997-10-01T00:00:00.000Z</StatusDate><Source id="265225" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00226"><Name>Bradykinin receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14005">Alkermes plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>COc1ccc(cc1)C[C@@H](CN[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](Cc3cccs3)NC(=O)CNC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)N)O</Smiles></StructureSmiles><Deals><Deal id="124253" title="ALZA to acquire option for rights to Alkermes's labradimil worldwide"/></Deals><PatentFamilies><PatentFamily id="1678711" number="WO-2008000803" title="Identification and use of GPRC variants in the treatment and diagnosis of Parkinson's disease"/><PatentFamily id="1807700" number="WO-2005059115" title="Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers"/><PatentFamily id="2088252" number="WO-09218529" title="Increasing blood-brain barrier permeability with permeabilizer peptides."/><PatentFamily id="275660" number="WO-09528947" title="Permeabilizer Peptides For Increasing Blood-Ocular Barrier Permeability"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alkermes plc" id="14005"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of South Florida" id="20677"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Diaxonhit" id="28238"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>